Log In
BCIQ
Print this Print this
 

EBV-CTL

  Manage Alerts
Collapse Summary General Information
Company Memorial Sloan Kettering Cancer Center
DescriptionEpstein-Barr virus (EBV)-specific cytotoxic T lymphocytes
Molecular Target
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Non-stem cell
Latest Stage of DevelopmentPhase II
Standard Indication Cancer (unspecified)
Indication DetailsTreat Epstein-Barr virus (EBV)-associated lymphomas and lymphoproliferative disorders in patients who are ineligible for any other trials of cell therapy; Treat Epstein-Barr virus (EBV)-positive lymphoproliferative disease and EBV-associated malignancies following allogeneic hematopoietic stem cell transplantation (HSCT)
Regulatory Designation U.S. - Breakthrough Therapy (Treat Epstein-Barr virus (EBV)-positive lymphoproliferative disease and EBV-associated malignancies following allogeneic hematopoietic stem cell transplantation (HSCT));
U.S. - Expanded Access (Treat Epstein-Barr virus (EBV)-associated lymphomas and lymphoproliferative disorders in patients who are ineligible for any other trials of cell therapy);
U.S. - Orphan Drug (Treat Epstein-Barr virus (EBV)-positive lymphoproliferative disease and EBV-associated malignancies following allogeneic hematopoietic stem cell transplantation (HSCT));
EU - Orphan Drug (Treat Epstein-Barr virus (EBV)-positive lymphoproliferative disease and EBV-associated malignancies following allogeneic hematopoietic stem cell transplantation (HSCT));
EU - PRIority MEdicines (PRIME) (Treat Epstein-Barr virus (EBV)-positive lymphoproliferative disease and EBV-associated malignancies following allogeneic hematopoietic stem cell transplantation (HSCT))
PartnerAtara Biotherapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

$33.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/23/2014

Undisclosed

0

$33.0M

Get a free BioCentury trial today